Latigo Biotherapeutics Inc.
LTGO
NASDAQ19.84
USD
+0.54
- -
CIK
0002056611
ISIN
US5179541033
CUSIP
517954103
Return %
Stock
S&P500
1Y
10.21
19.43
3Y
10.21
76.01
5Y
10.21
74.94
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Nima Farzan
- Full Time Employees
- 59
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- Address
- 1300 Rancho Conejo Boulevard, Suite 305 Thousand Oak CA United States of America 91320
- IPO Date
- Aug 7, 2026
- CIK
- 0002056611
- Website
- latigobio.com
- Similar Companies
- Business
- Latigo Biotherapeutics Inc. is a clinical-stage biotechnology company focused on the discovery and development of targeted therapies for solid tumor cancers, with a emphasis on novel oncology platforms and drug candidates aimed at tumor-specific biology and enhanced therapeutic indices. Latigo operates in the U.S. market with research and development activities primarily centered in its corporate headquarters and laboratories in the United States, leveraging collaborations with academic and industry partners to advance preclinical and clinical programs. Main products and services: discovery and development of oncology therapeutics; preclinical and clinical candidate generation; target validation and biomarker development; formulation, manufacturing process development for early-stage clinical supply; translational research and pharmacology studies; strategic collaborations and out-licensing of programs to pharmaceutical partners; regulatory strategy support and Clinical Trial Planning; scientific advisory and outsourced research services. Latest major company changes: enters collaborations and strategic alliances with industry partners to advance pipeline programs; completes or participates in financing rounds to fund R&D activities; pursues potential acquisitions or asset acquisitions to broaden portfolio; launches or expands new product candidates within its oncology platform; undergoes corporate reorganizations or leadership changes to optimize strategic focus; implements operational scaling or facility expansions to support pipeline progression. Additional context: Industry and segments include biotechnology, oncology therapeutics, small-molecule and potential biologic modalities; target markets include global pharmaceutical collaborators, research institutions, and later-stage development partners; geographic footprint primarily United States with potential interactions in international clinical trial sites; founding year and headquarters location tied to its corporate registration in the United States; may have subsidiaries or parent company relationships as part of corporate structuring.
Inside Latigo Biotherapeutics' IPO: A Non-Opioid Pain Bet Goes Public
Latigo Biotherapeutics (NASDAQ:LTGO) Director James Tananbaum Buys 140,000 Shares
Latigo Biotherapeutics (NASDAQ:LTGO) Major Shareholder Foresite Capital Management V, Acquires 140,000 Shares
Latigo Biotherapeutics Announces New England Journal of Medicine Publication of Positive LTG-001 Abdominoplasty Clinical Trial Results in Moderate-to-Severe Acute Pain